149055 20260316125347.0 doi 10.1016/j.eprac.2023.10.131 sideral 142174 ART-2023-142174 eng Sánchez Malo, María José Importance of Growth Factors and Bone Maturation Ratio in the Response to Growth Hormone Therapy 2023 Objective The aim was to identify the influence of insulin-like growth factor I (IGF-1), IGF-binding protein-3 (IGFBP-3), and bone age (BA)/chronological age (CA) ratio on the response to GH therapy after 1 and 2 years of treatment and upon reaching final height. Methods Longitudinal, retrospective, observational study of 139 patients treated for idiopathic growth hormone deficiency. Variables examined during follow-up: (1) genetic background; (2) perinatal history; (3) anthropometry; (4) height velocity, BA, BA/CA and height prognosis; (5) analytical results (IGF-1, IGFBP-3). Final response variables: adult height (AH), AH with respect to target height, AH with respect to initial height prognosis, AH with respect to height at the start of treatment, and AH with respect to height at onset of puberty. Results Lower pretreatment IGF-1 levels and a greater increase in IGF-1 at the end of treatment imply a better response (r = −0.405, P = .007 and r = 0.274, P = .014, respectively), as does a greater increase in IGFBP-3 after 2 years of treatment and at the end of treatment (r = 0.207, P = .035 and r = 0.259, P = .020, respectively). A lower BA/CA ratio pretreatment and at the onset of puberty results in a better response (r = −0.502, P = .000 and r = −0.548, P = .000, respectively), as does a lower increase in BA and BA/CA ratio after the 1 and 2 years of treatment (r = −0.337, P = .000 and r = −0.332, P = .000, respectively). Conclusion Low pretreatment IGF-1, a greater BA delay with respect to CA pretreatment and at the onset of puberty, a greater increase in IGFBP-3 after 2 years of treatment, and a lower increase in BA and BA/CA ratio after 1 and 2 years of treatment imply a better long-term response. info:eu-repo/semantics/closedAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 3.7 2023 ENDOCRINOLOGY & METABOLISM 62 / 186 = 0.333 2023 Q2 T2 1.208 2023 Endocrinology 2023 Q1 Medicine (miscellaneous) 2023 Q1 Endocrinology, Diabetes and Metabolism 2023 Q1 7.6 2023 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Hidalgo Sanz, Juan Ferrer Lozano, Marta Labarta Aizpún, Jose Ignacio Universidad de Zaragoza (orcid)0000-0003-2832-2266 de Arriba Muñoz, Antonio Universidad de Zaragoza (orcid)0000-0002-2865-5813 1011 670 Universidad de Zaragoza Dpto. Microb.Ped.Radio.Sal.Pú. Área Pediatría 30, 1 (2023), 57-63 ENDOCRINE PRACTICE ENDOCRINE PRACTICE 1530-891X 881715 http://zaguan.unizar.es/record/149055/files/texto_completo.pdf Versión publicada 2619267 http://zaguan.unizar.es/record/149055/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:149055 articulos driver 2026-03-16-08:29:35 ARTICLE